PIIND PI Industries Q2 FY26 results (Jul–Sep 2025) and concall
P I Industries reported a challenging Q2 FY26 with a 16% YoY revenue decline to ₹18,723 million, primarily due to global agchem headwinds and domestic weather/regulatory issues. Despite this, the Pharma business showed strong 54% YoY growth, and new AgChem export products grew 38% in H1. The company maintains a resilient EBITDA margin and a robust CSM order book of $1.25 billion, anticipating recovery in Q4 FY26 and H2 2026 for the broader industry.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 15.7%, net profit down 19.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 2,221 | 1,901 | 1,787 | 1,900 | 1,872 −16% |
| EBITDA | 628 | 512 | 456 | 519 | 541 −14% |
| Net profit | 508 | 373 | 330 | 400 | 409 −19% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
